Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Financial Results (May 1, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 1, 2024
Period End
May 1, 2024
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported first quarter 2024 results in a press release furnished under Item 2.02 of this Form 8-K (Exhibit 99.1).

Total revenues were $515.3 milliona, up from $420.4 million in the first quarter of 2023, with net product sales of $509.0 million. INGREZZA first quarter net product sales were $506 million, which the company said grew 23% year over year, driven by strong underlying patient demand and improved gross-to-net dynamics. GAAP net income was $43.4 million, or $0.42 per diluted share, compared with a GAAP net loss of $76.6 million, or $0.79 per share, in the prior-year quarter.

Non-GAAP net income was $124.8 millionb, or $1.20 per diluted share. The first quarter 2024 GAAP results include an $89 million charge tied to the company's election to settle its convertible senior notes in cash. The company reaffirmed its 2024 INGREZZA net product sales guidance of $2,100 million to $2,200 million and updated its expense guidance, with GAAP R&D expense of $665 million to $695 million and GAAP SG&A expense of $920 million to $940 million.

GAAP R&D guidance includes approximately $34 millionc of development milestone expense tied to collaborations. Cash, cash equivalents and marketable securities totaled $1,911.0 million at March 31, 2024, compared with $1,719.1 million at December 31, 2023.

Pipeline progress included the April 2024 submission of two New Drug Applications to the FDA for crinecerfont in adult and pediatric classic congenital adrenal hyperplasia, FDA approval of INGREZZA SPRINKLE capsules on April 30, 2024, and positive Phase 2 top-line data for NBI-1065845 in major depressive disorder, where the company is engaging with the FDA on a path forward. The company also expects top-line Phase 2 data for NBI-1117568 and luvadaxistat in the third quarter of 2024.

Key Highlights

  1. Total revenues of $515.3 million in Q1 2024, compared with $420.4 million in Q1 2023; net product sales of $509.0 million.
  2. INGREZZA first quarter 2024 net product sales of $506 million, growing 23% year over year.
  3. GAAP net income of $43.4 million ($0.42 per diluted share) versus a GAAP net loss of $76.6 million ($0.79 per share) in Q1 2023; non-GAAP net income of $124.8 million ($1.20 per diluted share).
  4. Q1 2024 includes an $89 million charge from electing to settle convertible senior notes in cash.
  5. 2024 INGREZZA net product sales guidance reaffirmed at $2,100 million to $2,200 million; GAAP R&D guidance of $665 million to $695 million and GAAP SG&A guidance of $920 million to $940 million.
  6. Cash, cash equivalents and marketable securities of $1,911.0 million at March 31, 2024, up from $1,719.1 million at December 31, 2023.
  7. Pipeline: FDA approval of INGREZZA SPRINKLE on April 30, 2024; crinecerfont NDAs submitted for congenital adrenal hyperplasia; positive Phase 2 data for NBI-1065845 in major depressive disorder.

Frequently Asked Questions

  1. What drove the growth in INGREZZA sales in the first quarter of 2024?

    The company attributed the 23% year-over-year growth in INGREZZA first quarter net product sales of $506 million to strong underlying patient demand and improvement in gross-to-net dynamics.

  2. Why did GAAP results differ from non-GAAP results in Q1 2024?

    GAAP results include stock-based compensation, an $89 million charge tied to the election to settle convertible senior notes in cash, and other items excluded from non-GAAP measures. Non-GAAP net income was $124.8 million, compared with GAAP net income of $43.4 million.

  3. What is the company's 2024 guidance?

    The company reaffirmed INGREZZA net product sales guidance of $2,100 million to $2,200 million. It also provided GAAP R&D expense guidance of $665 million to $695 million, non-GAAP R&D of $600 million to $630 million, GAAP SG&A of $920 million to $940 million, and non-GAAP SG&A of $810 million to $830 million.

  4. What are the key regulatory and clinical developments reported?

    In April 2024, the company submitted two New Drug Applications to the FDA for crinecerfont in adult and pediatric classic congenital adrenal hyperplasia, received FDA approval for INGREZZA SPRINKLE capsules, and reported positive Phase 2 results for NBI-1065845 in major depressive disorder. For NBI-1065845, the company is engaging with the FDA on a path forward.